Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CYCN logo CYCN
Upturn stock ratingUpturn stock rating
CYCN logo

Cyclerion Therapeutics Inc (CYCN)

Upturn stock ratingUpturn stock rating
$2.36
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: CYCN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $1.27
Current$2.36
52w High $9.47

Analysis of Past Performance

Type Stock
Historic Profit -76.83%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.88M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 1
Beta 1.34
52 Weeks Range 1.27 - 9.47
Updated Date 09/15/2025
52 Weeks Range 1.27 - 9.47
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.69

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -89.51%
Operating Margin (TTM) -1797.85%

Management Effectiveness

Return on Assets (TTM) -24.15%
Return on Equity (TTM) -22.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4874142
Price to Sales(TTM) 3.62
Enterprise Value 4874142
Price to Sales(TTM) 3.62
Enterprise Value to Revenue 2.24
Enterprise Value to EBITDA 0.56
Shares Outstanding 3203310
Shares Floating 2467574
Shares Outstanding 3203310
Shares Floating 2467574
Percent Insiders 31.48
Percent Institutions 11.43

ai summary icon Upturn AI SWOT

Cyclerion Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company that focused on discovering, developing, and commercializing medicines for serious and rare diseases. It was spun out of Ironwood Pharmaceuticals in 2019 and ceased operations in March 2023.

business area logo Core Business Areas

  • Soluble Guanylate Cyclase (sGC) Stimulators: Focused on developing sGC stimulators to modulate nitric oxide (NO) signaling for therapeutic benefit.

leadership logo Leadership and Structure

Peter Hecht was the CEO. The company had a typical biotech organizational structure with departments focused on research, development, clinical operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • CY6463: A central nervous system (CNS)-penetrant sGC stimulator being developed for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). It did not reach commercialization. Market share unavailable as it never reached commercialization. Competitors unknown because this condition is so rare that there are no current competing medications.
  • Praliciguat: An oral sGC stimulator being developed for sickle cell disease and heart failure with preserved ejection fraction (HFpEF). It did not reach commercialization before the company ceased operations. Market share unavailable as it never reached commercialization. Key competitors that have drugs in the market targeting similar mechanism include: Vericiguat (BAY 1021189).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and regulated. Cyclerion focused on rare diseases, a niche market with high unmet medical needs but also high development risks.

Positioning

Cyclerion positioned itself as an innovator in sGC stimulation. The company focused on developing novel therapies for diseases with high unmet needs.

Total Addressable Market (TAM)

The TAM for the indications Cyclerion was targeting (sickle cell disease, HFpEF, MELAS) was potentially significant (billions of USD). Cyclerion's position was early-stage development, so it was far from capturing any meaningful market share.

Upturn SWOT Analysis

Strengths

  • Novel sGC stimulator technology
  • Experienced management team
  • Focus on rare diseases

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trials
  • Lack of marketed products

Opportunities

  • Potential for orphan drug designation
  • Strategic partnerships
  • Expansion to new indications

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Funding limitations

Competitors and Market Share

competitor logo Key Competitors

  • VRTX
  • MRK
  • BMY

Competitive Landscape

Cyclerion was a small player competing against large, established pharmaceutical companies. Its sGC stimulator technology was its main competitive advantage, but clinical trial success was essential.

Growth Trajectory and Initiatives

Historical Growth: Cyclerion did not achieve commercial-stage growth. Its growth depended on successful clinical trial outcomes.

Future Projections: N/A as the company ceased operations.

Recent Initiatives: The company focused on advancing praliciguat and CY6463 through clinical trials. It attempted to secure additional funding.

Summary

Cyclerion Therapeutics was a high-risk, high-reward biotech company focused on a novel therapeutic target, sGC stimulation. It ceased operations due to its inability to secure additional funding and/or favorable clinical outcomes. Its strengths included its innovative technology and focus on rare diseases, but it faced significant financial and clinical challenges. Ultimately, the company was unable to navigate these challenges successfully and dissolved.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • SEC filings
  • Industry reports

Disclaimers:

This analysis is based on publicly available information and historical data. It should not be considered investment advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cyclerion Therapeutics Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2019-04-02
CEO, President & Director Dr. Regina M. Graul Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.